introduction Diffuse large B-cell lymphoma (DLBCL) accounts for approximately 40% of all new cases of non-Hodgkin's lymphoma (NHL) in Denmark [1] . Since the mid 1970s, the standard treatment of DLBCL has consisted of combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) or CHOP-like regimens [2, 3] . However, <40% of patients with advanced-stage DLBCL remain free from progression at 5 years [2] . With the addition of rituximab, response rates (RR) and overall survival (OS) have improved significantly, defining rituximab combined with CHOP or CHOP-like chemotherapy as the new standard treatment in CD20 positive DLBCL [4] [5] [6] [7] [8] [9] [10] [11] . However, patients with an unfavorable prognosis according to the International Prognostic Index remain at high risk for early treatment failure. Different approaches have been pursued to improve outcome for these high-risk patients. Dose-dense CHOP given at 2-week intervals (CHOP-14) and addition of etoposide (CHOEP- 14) , as reported in the NHL-B1 and B2 studies have improved RR and survival [12, 13] . However, the MInT (MabThera International Trial) study showed that the addition of rituximab abolished the beneficial effect of etoposide in younger good-risk patients [age-adjusted International Prognostic Index (aaIPI) <2] [9] .
The NHL-B1 trial indicated that the CHOEP-14 regimen was feasible with acceptable toxicity. Further, dose intensification of CHOEP (Mega-CHOEP) was tested by the German HighGrade Non-Hodgkin's Lymphoma Study Group (DSHNHL) in a phase III study, which also included rituximab (R-CHOEP-14) [14] . The study demonstrated an inferior complete remission (CR) rate and OS compared with the R-CHOEP-14 control arm [15] , which was found to result in an impressive OS rate of 83% after 29 months. The Spanish PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatia Maligna) Group reported a phase II study using dose-adjusted treatment with etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (EPOCH) plus rituximab in 71 young patients with aaIPI >1 and observed a 61% OS rate at 5 years [16] . A phase II study in 38 younger, primarily high risk (aaIPI 2-3), patients with DLBCL treated with R-CHOEP-14 resulted in a 2-year OS of 79% [17] . The GIMURELL (Gruppo Italiano Multiregionale Linfomi e Leucemie) Group carried out a nonrandomized phase II trial using rituximab combined with high-dose chemotherapy (HDT) followed by autologous stem-cell transplantation (ASCT) in young patients with high-risk disease and obtained a 4-year OS rate of 80% [18] . However, a 2008 Cochrane metaanalysis concluded that consolidation with HDT-ASCT does not improve event-free survival or OS [19] . This is further supported in a recent abstract presented by the GOELAMS (Groupe Ouest-Est des Leucémies Aigués et autres Maladies du Sang) group trial comparing R-CHOP-14 with RHigh Dose Treatment (R-HDT) in a randomized trial including DLBCL patients; they found that R-CHOP-14 is as efficient but with less toxicity [20] .
Consequently, in the era of rituximab the optimal treatment of young high-risk DLBCL patients remains to be established. Currently, this group of patients is treated diversely: based on the results of the MINT study, many physicians administer R-CHOP-21 or R-CHOP-14 also to high-risk patients, whereas others rely on a potential beneficial effect of etoposide using R-CHOEP-14. To address the question whether or not the addition of etoposide is beneficial in young high-risk DLBCL patients, we carried out a population-based study comparing R-CHOP-14 with R-CHOEP-14 in young DLBCL patients diagnosed between 1 January 2004 and 31 December 2008 in Denmark. To our knowledge, this is the first study comparing R-CHOP-14 and R-CHOEP-14 in this group of patients.
patients and methods patients
The population-based lymphoma registry of the Danish Lymphoma Group (Lyfo) includes all newly diagnosed NHL patients in Denmark, enabling the prospective collection of clinical and pathological data. At the end of 2009, >14 000 lymphoma patients were registered. All hematological units in Denmark are obligated to report to Lyfo all patients at diagnosis at the time of relapse or death. To certify the completeness of Lyfo, the registry is cross-referenced with the Central Danish Cancer Registry and Central Registry of Pathology.
We used this registry to perform a study involving young patients with DLBCL who were newly diagnosed between 1 January 2004 and 31 December 2008. Patients aged 18-60 years with newly diagnosed DLBCL, as defined by a hematopathologist according to the World Health Organisation (WHO) criteria [21] , were eligible for the analysis. Patients had to have two or more risk factors according to the aaIPI: Ann Arbor stage III-IV [22] , elevated lactate dehydrogenase (LDH) levels or Eastern Cooperative Oncology Group performance status (PS) 2-4 [23] . Only patients treated with immunochemotherapy combining rituximab with either CHOP-14 or CHOEP-14 were included.
Exclusion criteria were a history of indolent lymphoma, relapse from previous NHL, secondary lymphoma after previous chemotherapy or radiotherapy for another disease, primary central nervous system (CNS) involvement, testis lymphoma, human immunodeficiency virus/acquired immunodeficiency syndrome-associated lymphoma, posttransplantation lymphoproliferative disease or other malignant neoplasms.
treatment
Patients were treated at 12 different centers. At two centers, only R-CHOP-14 was used, whereas at the remaining 10 centers, R-CHOP-14 or R-CHOEP-14 treatment could be chosen. Table 1 shows the schedules of the regimens.
Patients received 6-8 cycles depending on the response to treatment evaluated by computed tomography (CT) scan after 3 or 4 cycles.
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Radiotherapy (30-40 Gy) was administered in case of bulky disease and/or extranodal disease and residual masses according to local standards.
end points and assessment of response
The primary end point was OS, defined as time from diagnosis to death from any cause. Secondary end points were (i) overall response rate (ORR), including CR, complete remission unconfirmed (CRu) and partial remission (PR), (ii) progression-free survival (PFS) defined as time from diagnosis until progression or death from any cause and (iii) safety/ frequency of treatment-related toxicity.
Patients without a PFS or OS event were censored on the last day as having valid information for that end point.
Response was assessed by the treating physician after the end of treatment according to the Cheson et al. criteria [24] . A CT scan was carried out 6-8 weeks after the last day of treatment.
During the first 2 years, clinical and biochemical follow-up occurred every 3 months and thereafter every 6 months. A CT scan was carried out every 6 months for the first 2 years of the follow-up period.
statistical analysis
The main analyses were done on an intention-to-treat basis. Baseline characteristics were analyzed using the chi-square test or Mann-Whitney test. OS was measured from the time of diagnosis until death or follow-up and estimated according to the Kaplan-Meier method. PFS was measured from the time of diagnosis until progression or death of any cause. Cox proportional hazards regression analysis was applied to determine the relative prognostic impact of baseline variables and treatment regimens. The multivariate analysis included age, sex, WHO PS, and treatment regimen. Survival status for the entire patient cohort was extracted on 17 December 2009 from the Central Person Registry. Patients receiving highdose chemotherapy with stem-cell support (7 R-CHOP-14, 5 R-CHOEP-14) were censored from Kaplan-Meier analysis from the date of stem-cell infusion. Differences between groups were analyzed using the log-rank test and were regarded as significant if P values were <0.05. All P values in OS and PFS analysis were done by Cox proportional hazard model using likelihood statistic. Statistical analyses were carried out using the software PASW version 18 and STATA version 11. results patients A total of 260 patients fulfilled the inclusion criteria regarding diagnosis, age and risk factors. Of these, 52 patients were excluded from the analysis for the following reasons: 20 patients had primary CNS or testis involvement, 43 patients did not receive rituximab (all treated in 2004-2005) and 10 patients received regimens other than R-CHOP or R-CHOEP. In addition, 28 patients were excluded from the analysis because they received either R-CHOP-21 (n = 24) or R-CHOEP-21 (n = 4) tri-weekly, leaving 159 patients who fulfilled all inclusion criteria. Of these, 98 (62%) patients were treated with R-CHOP-14 and 61 (38%) were treated with R-CHOEP-14 ( Figure 1) . Patient characteristics are presented in Table 2 . No differences were seen between the two treatment groups regarding clinical presentation and risk factors, including gender, extranodal involvement, number of nodal sites, bone marrow (BM) involvement, maximum tumor diameter, B symptoms, PS, elevated LDH, Ann Arbor stage, bulky disease and aaIPI. However, the age distribution was found to be different between the two groups with a higher median age in the R-CHOP-14 group (56 versus 49 years, P < 0.001). The treatment groups did not differ with regard to the number of cycles, prophylactic CNS treatment or radiotherapy. There was a nonsignificant tendency to an unbalance between the groups in regard to BM involvement.
response to therapy
The ORR for R-CHOP-14 was 78% compared with 90% for R-CHOEP-14. CR was 43% versus 53%, CRu 20% versus 25% and PR was 14% versus 13%, respectively (Table 3) . Twenty-one patients who obtained a response to treatment relapsed, 14 in the R-CHOP-14 group and 7 in the R-CHOEP-14 group with no significant difference (NS).
survival
The median follow-up time was 27 months for PFS and 27.9 months for OS. The 4-year OS for the R-CHOP-14 group was 62% versus 75% in the R-CHOEP-14 group (P = 0. 04) (Figure 2 ). Correspondingly, PFS was 58% in the R-CHOP-14 group and 70% for patients treated with R-CHOEP-14 (P = 0.02) (Figure 3) .
A multivariate analysis was carried out for the following variables: treatment regimen, gender, age and PS (0-1/2-4) and revealed that the treatment regimen, HR 0.5 (95% CI 0.2-1.0, P = 0.04), gender HR 2.6 (95% CI 1.3-5.1, P = 0.004) and PS HR 2.5 (95% CI 1.4-4.6, P = 0.004) were of significant importance in relation to OS. In relation to PFS, treatment regime HR 0.5 (95% CI 0.3-0.9, P = 0.03), gender HR 2.1 (95% CI 1.1-3.8, P = 0.02) and PS HR 2.0 (95% CI 1.1-3.6, P = 0.02) also were of significant importance.
We compared the results of one of the large national centers, in which patients were exclusively treated with R-CHOP-14, to the results of treatment with R-CHOP-14 from those centers, where R-CHOP-14 or R-CHOEP-14 were available as treatment options. This was done in order to estimate the likelihood of selection of R-CHOP-14 over R-CHOEP-14 due to the presence of comorbidity. OS was found to be similar for patients treated at the center where only R-CHOP-14 was available and the overall R-CHOP-14-treated patient population (data not shown). The median cycle duration was 14.7 and 14.8 days in the two cohorts, respectively (NS). Toxicity was assessed by analyzing treatment-associated death and toxicity-related admission to hospital during treatment. Death before the first evaluation was categorized as treatment-related death and no difference was observed between the two groups (R-CHOP-14 n = 8, R-CHOEP-14 n = 2). In the R-CHOP-14 group, 43% of patients developed Common Toxicity Criteria (CTC) grade III/ IV toxicity during treatment that led to admission to hospital compared with 66% in the R-CHOEP-14 group (P = 0.005).
discussion
In the era of rituximab, the question of the optimal treatment of young patients with high-risk DLBCL remains open. The lack of evidence regarding the optimal treatment has left physicians with a choice of treatments ranging from R-CHOP-21 to R-CHOEP-14. No study has prospectively compared the outcome between R-CHOP-14 and R-CHOEP-14, and our population-based comparison of these two regimens therefore seems relevant. Our study shows that patients treated with R-CHOEP-14 have a superior 4-year OS of 75% compared with 62% for patients treated with R-CHOP-14 (P = 0.04). The benefit of etoposide on outcome is further substantiated by a significantly improved PFS.
This subgroup of patients is a minor part of the whole DLBCL cohort, which results in a small sample size despite it is population based but this is a limit to this study-larger cohorts would obviously be preferable.
It could be argued that our study may contain a bias due to some clinicians avoiding treatment with R-CHOEP-14 because of a high PS or severe comorbidity. However, the two treatment 
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Annals of Oncology groups in this study were highly comparable regarding most characteristics of major importance, including all baseline aaIPI factors and sex. Moreover, our study comprised a young patient group, in whom severe comorbidity is expected to be less prominent. A comparison of patients treated at one center that exclusively used the R-CHOP-14 regimen with patients treated with this regimen at all other centers revealed that survival between these two groups was similar. This lends further support to the argument that patients treated with R-CHOP-14 or R-CHOEP-14 in this study were not selected due to PS or comorbidity but due to physician preference based on an expected benefit of etoposide treatment. There were no differences in the number of cycles or the dose intensity between the two groups.
Age is known to be a predictive factor for response and OS in DLBCL. In addition, recent results seem to suggest that female gender is associated with superior outcome in the era of rituximab [25] . Due to the retrospective nonrandomized nature of this study, there was a slight difference between groups regarding the age (49 versus 56 years) and sex distribution.
We therefore carried out a Cox multivariate analysis on the impact of age, sex, PS and treatment regimen. This multivariate analysis confirmed that treatment regimen and gender were predictors of OS and PFS. In addition, the PS was of importance for OS, whereas age was not predictive, indicating that the difference in the age distribution between the two groups was not of importance.
R-CHOEP-14 was found to result in increased toxicity compared with R-CHOP-14, including a significantly higher percentage of hospital admissions during treatment. The increased toxicity did not translate into a higher treatment-related death rate, which was shown to be low in both groups. Long-term toxicity of etoposide was not seen in the NHL-B1 [12] study regarding secondary myelodysplastic syndrome (MDS)/acute myelogenous (myeloblastic, myelocytic) leukaemia (AML), and none of the patients in the present study developed MDS/AML. Given that the intention is cure and a potential long-term survival benefit, we consider the increased rate of hospital admission during treatment acceptable.
A prospective study by Adde et al. [17] was the first published data on R-CHOEP in this high-risk patient group. The investigators reported an OS of 79% at 2 years. A recent abstract summarizing data from the randomized study of the DSHNHL demonstrated an OS of 84% at 29 months for R-CHOEP-14 [15] . Our study also with a relative short followup of 28 months is in accordance with these two studies. Longer follow-up is for all these studies preferable, despite most patients have an early relapse. Other attempts to increase OS in this young high-risk group have included up-front HDT with ASCT [14] . However, a Cochrane review revealed that despite higher CR rates there is no benefit for ASCT as part of first-line treatment. After this review was published, a single study reported an OS of 80% at 4 years after HDT with ASCT [18] and an abstract from GOELAMS [20] did not favor up-front HDT compared with R-CHOP-14. Thus, the role for HDT is still debatable.
Increasing dose intensity has been further tested by the DSHNHL group, who explored a Mega-CHOEP-R regimen. The investigators concluded that further escalation of chemotherapy was too toxic and did not improve the CR rate or OS compared with R-CHOEP-14 [14] . A recent abstract from the Nordic lymphoma group reported a phase II study of DLBCL patients £65 years treated with R-CHOEP-14 · 6 + High Dose Methotrexate · 1 and High Dose cytarabine · 1. They report a CR/CRu of 69% and a 3-year OS of 80% with low treatment-related death [26] .
Thus, considering the balance between defining the most effective treatment with minimal toxicity, the R-CHOEP-14 regimen has demonstrated a high efficacy with a tolerable toxicity.
Our analysis is the first in the rituximab era to compare R-CHOP-14 with R-CHOEP-14 in young patients with high-risk DLBCL according to aaIPI. It is a retrospective, populationbased, nonrandomized study, which included 98% of all young patients diagnosed with DLBCL in Denmark in the defined period and consisted of comparable patient cohorts in the two treatment groups. Large randomized controlled fully matched studies with long follow-up are preferable. However, our data suggest that R-CHOEP-14 regime should be considered for treatment outside clinical trials in this subgroup of patients, who generally have a poor prognosis.
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